Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region

Study Overview
=================
Brief Summary
-----------------
Several publications document the occurrence of prolonged or late-onset symptoms beyond 3 weeks after the first clinical manifestations of SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory events or other mechanisms that are not yet well understood. The psychosomatic origin secondary to psychiatric disorders prior to the infection or in reaction to it is also to be evoked. The identification of the clinical manifestations observed, and their clinical and paraclinical evolution are essential to better understand the natural evolution of COVID-19, to specify the physiopathological mechanisms and to identify potential avenues of management for the patients. In addition, the impact of COVID-19 infection on primary care visits is not known. In general practice, these patients benefit from explorations and even diagnoses that may explain the persistence of symptoms (autoimmune diseases, thrombosis, somatoform disorders, hyperventilation syndrome, etc.). The objective of the COCO_Vi_LATE project is to carry out a cross-sectional study of patients presenting persistent and/or recurrent symptoms after an infection with SARS-COV-2 who will be compared to individuals with a short form of infection with COVID-19

Official Title
-----------------
Coordinated Research on Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With SARS-COV-2 Infection: a Transversal Study in Town in the Hauts de France Region

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Questionnaire
* Other: medical consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A- For COVID cases: Consultation in a city doctor's office Positive SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology Patient symptomatic or not Definition of symptomatic : Anosmia OR CT scan suggestive of COVID 19 OR ≥ 2 symptoms contemporaneous with virologic sampling among: asthenia, cough, dyspnea, fever, myalgias, dysgeusia, diarrhea AND not present previously at diagnosis B-. For NON COVID cases: Consultation in a city doctor's office No known COVID+ serology No known RT- PCR SARS-CoV-2 No clinical suspicion of COVID-19 infection Exclusion Criteria: Minor patient Refusal to participate Patient under protection Patient requiring hospitalization for COVID-19 (excluding non-emergency hospitalization) Patient consulted for the following reason only: treatment monitoring, treatment renewal or certificate, hospital discharge

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 positive<br> | Other: Questionnaire<br>* Questionnaire SSD-12 and EQ5D5L<br>Other: medical consultation<br>* Medical consultation during the visit with data collection<br>|
| COVID-19 negative<br> | Other: Questionnaire<br>* Questionnaire SSD-12 and EQ5D5L<br>Other: medical consultation<br>* Medical consultation during the visit with data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the reasons for consultation between patients with a history of Covid 19 and those who have not been infected with SARS-CoV-2. | The judgement criterion will be the reasons for consultation standardized with the CISP-2 classification (International Classification of Primary Care). | At day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To Assess the presence of somatoform disorders between COVID-19 and non-COVID-19 patients. | The assessment will be done using the international SSD-12 scale (Symptom Disorder-B Criteria Scale). The SSD-12 is composed of 12 items; each of the three psychological subcriteria is measured by four items (cognitive aspects; affective aspects; behavioral aspects). | At day 1 | 
| To compare the quality of life of COVID-19 patients with that of non-COVID-19 patients. | The EQ-5D-5L scale is composed of - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'. | At day 1 |